Wolverine
BPC-157 + TB-500 community blend
A community name for combining BPC-157 and TB-500. Evidence for either component does not establish the safety or effectiveness of the combination.
Mechanism
Combines proposed cytoprotective and actin-related tissue signaling
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| BPC-157 component schedule | 250 mcg | 500 mcg/day | Twice daily | Morning and evening | Subcutaneous | Community-reported |
| TB-500 component schedule | 2–2.5 mg | 4–5 mg/week | Twice weekly | Evenly spaced | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
BPC-157 and TB-500 presentations and blend ratios vary. Each labeled component amount must be known before a combined calculation is possible.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
BPC-157 and TB-500 presentations and blend ratios vary. Each labeled component amount must be known before a combined calculation is possible.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
No controlled human study has established a fixed ratio, interaction profile, or long-term safety for this blend.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.